Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients (ESCAPE)

11. januar 2010 opdateret af: Heidelberg University

Molecular Mechanisms of Disease Progression and Renoprotective Pharmacotherapy in Children With Chronic Renal Failure

In children with chronic kidney disease, progression to end-stage renal failure is associated with high patient morbidity and poor quality of life. In adults, inhibition of the renin angiotensin system (RAS) slows down the rate of renal failure progression. This concept is as yet unproven in children, in whom chronic renal failure (CRF) is more commonly due to hypo/dysplastic malformations than to acquired glomerulopathies as typical for adult chronic kidney disease. The current project aims at assessing the genetic and molecular mechanisms and cardiovascular consequences of progressive CRF and to develop a strategy of pharmacological renoprotection in children.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Chronic kidney diseases affecting the nephron mass are characterized by a progressive decline of glomerular filtration rate (GFR) occurring irrespectively of the cause of the renal damage once a critical number of nephrons has been lost. Current clinical research efforts focus on preventive strategies to slow down or arrest disease progression. Systemic hypertension and glomerular hyperfiltration with resulting proteinuria and activation of vasoactive, profibrotic and proinflammatory systems have been identified as major causes of further nephron damage. Angiotensin converting enzyme (ACE) inhibitors are not only potent antihypertensive agents but also reduce proteinuria, glomerulosclerosis and tubulointerstitial fibrosis via reduction of the local angiotensin tone in the kidney, and have been demonstrated to slow down renal failure progression in adult patients. Childhood-onset ESRD is a rare but particularly devastating disease with poor life expectancy and quality of life. Chronic renal failure in children is caused by a different spectrum of nephropathies than in adults, with a preponderance of congenital or inherited abnormalities. Since hypertension, proteinuria and tubulointerstitial fibrosis are also common in pediatric chronic renal failure, there is a rationale for pharmacological renoprotection by ACE inhibition in children. The prospective, randomized European clinical trial launched by our consortium will provide the critical mass to assess several aspects of renoprotective therapy in children. Specifically, the trial is designed to address the following scientific objectives:

Objective 1 is to evaluate whether ACE inhibition is equally effective in slowing down the progression rate of chronic renal failure in children with different congenital and acquired renal disorders. 400 pediatric patients will be stratified according to their underlying diseases, and the rate of loss in glomerular filtration rate will be assessed from 6 months before to 5 years after start of treatment with the ACE inhibitor ramipril.

Objective 2 of the trial is to evaluate whether renal failure progression in patients treated with a fixed dose of ramipril can be further slowed down by additional antihypertensive treatment, achieving a blood pressure below the 50th percentile. To this end, patients will be randomized upon initiation of ramipril to either intensified (aiming below 50th percentile of 24-hour mean arterial pressure) or conventional antihypertensive treatment.

Several gene polymorphisms have been described that may affect the rate of renal failure progression and/or the individual susceptibility to ACE inhibition. These polymorphisms include genes encoding for key proteins of the renin-angiotensin system and extracellular matrix turnover. In addition, we will screen for novel polymorphisms in genes determining structural proteins of the glomerular filter, and search for gene mutations causing renal hypo-/dysplasia. Objective 3 is to evaluate whether any of these mutations predict spontaneous disease progression and the therapeutic response to ACE inhibition and intensified blood pressure control.

Glomerular endothelin (ET1) synthesis is upregulated in chronic renal failure, and urinary ET1 excretion is correlated with disease progression. ET1 antagonists partially preserve renal function and decrease proteinuria independent of the angiotensin tone. Objective 4 of the trial is to assess ET1 turnover before and after start of ACE inhibition, and to evaluate a possible predictive role of ET1 and/or ET1 degrading peptidase excretion for the persistence of proteinuria and disease progression during ACE inhibition and intensified antihypertensive therapy.

Long-term survival of children with chronic renal failure is compromised by precocious atherosclerosis and excessive cardiovascular morbidity. Objective 5 is to assess and correlate prospectively the metabolic causes and morphological consequences of uremic cardiovascular disease in children, and to define their relationship with disease progression during ACE inhibition and intensified blood pressure control. Homocysteine metabolism, apolipoprotein variability, gene polymorphisms putatively involved in atherosclerosis, inflammation states, myocardial function and carotid intima-media thickness will be assessed and compared to a reference group of age-matched healthy children.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

400

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Frankrig
      • Paris, Frankrig, 75015
        • Hopital Necker, Division of Pediatric Nephrology
      • Paris, Frankrig, 75015
        • Inserm U574
      • Strasbourg, Frankrig, 67098
        • Hopiteaux Universitaires de Strasbourg
  • Italien
      • Genoa, Italien, 16148
        • G.Gaslini Institute, Nephrology Unit
      • Milano, Italien, 20122
        • Azienda Ospedaliera, Istitui Clinici di Perfezionamento, Servizio die Emodialisi Pediatrica
      • Padova, Italien, 35128
        • Azienda Ospedaliera die Padova. U.O. Nefrologia Dialisi e Trapianto - Dipartimento di Pediatria
      • Rome, Italien, 00165
        • Ospedale Pediatrico Bambino Gesù, Division of Nephrology and Dialysis
      • Torino, Italien, 10126
        • Ospedale Infantile Regina Margherita, U.O.A. Nefrologia, Dialisi, Trapianto
  • Kalkun
      • Adana, Kalkun, 01330
        • Cukurova University School of Medicine, Dept. of Pediatric Nephrology
      • Ankara, Kalkun, 06100
        • Hacettepe University, Faculty of Medicine, Pediatric Nephrology and Rheumatology
      • Istanbul, Kalkun, 34303
        • Istanbul University, Cerrahpasa Medical Faculty, Dept, of Pediatrics
      • Istanbul, Kalkun, 34390
        • University of Istanbul, Istanbul Medical Faculty, Dept. of Pediatrics
      • Izmir, Kalkun, 35100
        • Ege University Medical Faculty, Dept. of Pediatric Nephrology
  • Litauen
      • Vilnius, Litauen, 2600
        • Vilnius University Children's Hospital, Pediatric Department, Nephrology Unit
  • Polen
      • Cracow, Polen, 30-663
        • Jagellonian University Medical College, Department of Pediatric Nephrology
      • Gdansk, Polen, 80-211
        • Medical University of Gdansk, Pediatric Nephrology Department
      • Szczecin, Polen, 71-344
        • Clinic of Pediatrics, Pomeranian Academy of Medicine
      • Warsaw, Polen, 04-736
        • Children's Memorial Health Hospital, Nephrology and Kidney Transplantation Department
  • Portugal
      • Porto, Portugal, 4202 - 451
        • Hospital S. Joao-Faculade de Medicina do Porto, Dept. of Pediatrics
  • Schweiz
      • Zürich, Schweiz, 8032
        • University Children's Hospital, Nephrology Unit
  • Serbien
      • Belgrade, Serbien, 11000
        • Faculty of Medicine Belgrade, University Children's Hospital, Nephrology Unit
  • Sverige
      • Stockholm, Sverige, 14186
        • Karolinska Institute, Huddinge University Hospital, Dept. of Pediatrics
  • Tjekkiet
      • Prague, Tjekkiet, 150 18
        • University Hospital Motol, 1st Department of Pediatrics
  • Tyskland
      • Berlin, Tyskland, 13353
        • Humboldt University Berlin, Charité Children's Hospital, Department of Pediatric Nephrology
      • Essen, Tyskland, 45122
        • University Hospital Essen, Department of Pediatrics, Pediatric Nephrology Unit
      • Hamburg, Tyskland, 20246
        • University Hospital Hamburg-Eppendorf, University Children's Hospital, Dept. of Pediatric Nephrology
      • Hannover, Tyskland, 30623
        • Hannover Medical School, Children's Hospital Div. II, Pediatric Nephrology
      • Heidelberg, Tyskland, 69120
        • Division of Pediatric Nephrology, Children's Hospital, University of Heidelberg
      • Leipzig, Tyskland, 04129
        • Urban Hospital St. Georg, Department of Pediatrics, Pediatric Nephrology Unit
      • Mainz, Tyskland, 55131
        • Johannes Gutenberg University Mainz, Department of Pediatrics,
      • Marburg, Tyskland, 35037
        • Philipps University Marburg, Dept. of Pediatrics
      • Rostock, Tyskland, 18050
        • University Children's Hospital, Dept. of Nephrology
  • Ungarn
      • Budapest, Ungarn, 1083
        • Semmelweis University Budapest, 1st Department of Pediatrics

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

3 år til 18 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 3-18 years
  • Moderate state of renal failure (creatinine clearance 15 - 75 ml / min / 1.73 m²)
  • Mean arterial blood pressure (ABPM) > 50.percentile and/or antihypertensive treatment
  • Written informed consent

Exclusion Criteria:

  • Age <3 years or >18 years at start of study
  • Unstable clinical condition (vomiting, anorexia, etc) or superimposed important disease
  • Unilateral or bilateral renal artery stenosis
  • Urological surgery possibly affecting renal function expected during study period
  • Insufficient compliance with prescribed antihypertensive medication during the run-in period
  • Secondary renal diseases such as lupus, amyloidosis and primary hyperoxaluria, and patients treated with immunosuppressive agents (including corticosteroids)
  • Severe primary cardiac disease, hepatic insufficiency and malabsorption syndrome
  • Erythropoietin or growth hormone therapy with a duration of less than 3 months prior to run-in period
  • Pregnancy

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Conventional BP Control
Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
Medicin: ACE Inhibition
ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Andre navne:
  • Delix
Medicin: Intensified Blood Pressure Control
Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Medicin: Add-on Angiotensin Receptor Blockade
In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Andre navne:
  • Micardis
Eksperimentel: Intensified BP Control
Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
Medicin: ACE Inhibition
ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Andre navne:
  • Delix
Medicin: Intensified Blood Pressure Control
Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Medicin: Add-on Angiotensin Receptor Blockade
In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Andre navne:
  • Micardis

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Time interval to renal 'loss' as defined by an absolute decrease in creatinine clearance by 50 % or attainment of renal replacement therapy.
Tidsramme: two-monthly
two-monthly

Sekundære resultatmål

Resultatmål
Tidsramme
Effect of treatment on urinary protein excretion
Tidsramme: two-monthly
two-monthly
Effect of treatment on blood pressure
Tidsramme: two-monthly
two-monthly
Safety of treatment
Tidsramme: initially weekly, than two-monthly
initially weekly, than two-monthly

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Heidelberg University

Samarbejdspartnere

Baxter Healthcare Corporation
Boehringer Ingelheim
Aventis Pharmaceuticals
European Commission

Efterforskere

  • Ledende efterforsker: Franz Schaefer, MD, University of Heidelberg, Children's Hospital
  • Ledende efterforsker: Otto Mehls, MD, University of Heidelberg, Children's Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 1998

Primær færdiggørelse (Faktiske)

1. juli 2007

Studieafslutning (Faktiske)

1. januar 2010

Datoer for studieregistrering

Først indsendt

15. september 2005

Først indsendt, der opfyldte QC-kriterier

15. september 2005

Først opslået (Skøn)

22. september 2005

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

12. januar 2010

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. januar 2010

Sidst verificeret

1. januar 2010

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • QLRT-2001-00908

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner